Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

This book represents the latest research on microbiota axes, with a special focus on the gut-skin axis and the role of microbial breast bacteria on human health communication. This book also contains discussions of the microorganism-derived products that can directly or indirectly be signals for our organs and systems. Gut dysbiosis, representing a disruption of intestinal integrity, can create aberrant physiological conditions (including immunological disorders, intestinal stress, and anxiety-like behavior), as well as high serum levels of microbial metabolites increasing oxidative stress dysfunctions and generalized inflammation. Much research in this field has been carried out in animal models, and establishing whether those findings translate to humans will be crucial but challenging. On the other hand, several studies conducted on humans have evaluated the link between fecal microbiota composition and quality of life by recruiting thousands of participants. As well as identifying bacterial genera associated with higher quality of life, they carried out metagenomic analyses that indicated that the potential of microorganisms to synthesize certain active metabolites, and especially their interrelation, may also correlate with general wellbeing. It is clear that many axes can influence our lives; the most important include “the gut-brain axis” and the “skin-gut-breast axis”. Together, the studies presented in this book have laid the foundations for a better understanding of the effects of gut microbiota on skin and on our body in general. The mechanisms that underlie them may represent the ideal focus for the initial efforts to explore the relevance of these axes for human wellbeing.

Medicine --- small–large intestine axis --- hydrogen sulfide --- Desulfovibrio --- bowel disease --- colitis --- gut microbiota --- microbiome --- maternal–fetal interface --- newborn --- child --- pediatric disease --- dysbiosis --- microbiota --- schizophrenia --- olanzapine administration --- weight gain --- sulfate reduction --- microbiota axis --- oral microbiota arthritis --- joint inflammation --- otitis media --- upper respiratory tract --- adenoid --- middle ear --- microbiota axes

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

This book represents the latest research on microbiota axes, with a special focus on the gut-skin axis and the role of microbial breast bacteria on human health communication. This book also contains discussions of the microorganism-derived products that can directly or indirectly be signals for our organs and systems. Gut dysbiosis, representing a disruption of intestinal integrity, can create aberrant physiological conditions (including immunological disorders, intestinal stress, and anxiety-like behavior), as well as high serum levels of microbial metabolites increasing oxidative stress dysfunctions and generalized inflammation. Much research in this field has been carried out in animal models, and establishing whether those findings translate to humans will be crucial but challenging. On the other hand, several studies conducted on humans have evaluated the link between fecal microbiota composition and quality of life by recruiting thousands of participants. As well as identifying bacterial genera associated with higher quality of life, they carried out metagenomic analyses that indicated that the potential of microorganisms to synthesize certain active metabolites, and especially their interrelation, may also correlate with general wellbeing. It is clear that many axes can influence our lives; the most important include “the gut-brain axis” and the “skin-gut-breast axis”. Together, the studies presented in this book have laid the foundations for a better understanding of the effects of gut microbiota on skin and on our body in general. The mechanisms that underlie them may represent the ideal focus for the initial efforts to explore the relevance of these axes for human wellbeing.

Medicine --- small–large intestine axis --- hydrogen sulfide --- Desulfovibrio --- bowel disease --- colitis --- gut microbiota --- microbiome --- maternal–fetal interface --- newborn --- child --- pediatric disease --- dysbiosis --- microbiota --- schizophrenia --- olanzapine administration --- weight gain --- sulfate reduction --- microbiota axis --- oral microbiota arthritis --- joint inflammation --- otitis media --- upper respiratory tract --- adenoid --- middle ear --- microbiota axes

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Polypharmacy is a necessary and important aspect of drug treatment; however, it becomes a challenge when the medication risks outweigh the benefits for an individual patient. Drug–drug interactions and the introduction of prescribing cascades are common features of polypharmacy, which can lead to ineffectiveness and increased risk of adverse drug reactions (ADR). Genes encoding CYP450 isozymes and other drug-related biomarkers have attracted considerable attention as targets for pharmacogenetic (PGx) testing due to their impact on drug metabolism and response. This Special Issue is devoted to explore the status and initiatives taken to circumvent ineffectiveness and to improve medication safety for polypharmacy patients. Specific areas include drug–drug interactions and consequences thereof in therapeutic management, including PK- and PD-profiling; the application of PGx-based guidance and/or decision tools for drug–gene and drug–drug gene interactions; medication reviews; development and application of deprescribing tools; and drivers and barriers to overcome for successful implementation in the healthcare system.

Medicine --- Pharmaceutical industries --- acute kidney injury --- early biomarker --- plasma neutrophil gelatinase-associated lipocalin --- soluble urokinase plasminogen activator receptor --- medication optimization --- older patients --- emergency department --- multimorbidity --- polypharmacy --- potentially inappropriate medication use --- older adults --- prevalence --- determinants --- chronic --- outpatient --- 2019 Beers criteria --- Ethiopia --- pharmacogenomics --- persons with diabetes --- drug–drug interactions --- drug–gene interactions --- cytochrome P450 --- SLCO1B1 --- drug interaction checkers --- adverse drug reactions --- pharmacogenetics --- personalized medicine --- phenprocoumon --- DOACs --- bleeding --- thromboembolism --- HLA --- drug hypersensitivity --- abacavir --- allopurinol --- flucloxacillin --- antiepileptic drugs --- cost-effectiveness --- shared medication record --- medication reconciliation --- drug information service --- hospital pharmacy service --- electronic prescribing --- electronic medical record --- clinical pharmacist --- CYP2D6 --- CYP2D7P --- CYP2D8P --- copy number variation --- CNV --- genotyping --- 5’nuclease assay --- HRM --- high resolution melting --- drug metabolization --- extracellular vesicles --- exosomes --- microvesicles --- pharmacogene expression --- medication review --- deprescriptions --- quality of life --- aged --- aged, 80 and over --- nursing homes --- deprescribing --- medication-based risk score --- health outcomes --- cytochromes --- CYP1A2 --- adverse drug reaction --- antipsychotics --- olanzapine --- clozapine --- loxapine --- children --- youth --- digital decision-support --- health services research --- general practice --- process evaluation --- antidepressants --- utility --- population-based --- appropriateness --- medication adherence --- digital health

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Polypharmacy is a necessary and important aspect of drug treatment; however, it becomes a challenge when the medication risks outweigh the benefits for an individual patient. Drug–drug interactions and the introduction of prescribing cascades are common features of polypharmacy, which can lead to ineffectiveness and increased risk of adverse drug reactions (ADR). Genes encoding CYP450 isozymes and other drug-related biomarkers have attracted considerable attention as targets for pharmacogenetic (PGx) testing due to their impact on drug metabolism and response. This Special Issue is devoted to explore the status and initiatives taken to circumvent ineffectiveness and to improve medication safety for polypharmacy patients. Specific areas include drug–drug interactions and consequences thereof in therapeutic management, including PK- and PD-profiling; the application of PGx-based guidance and/or decision tools for drug–gene and drug–drug gene interactions; medication reviews; development and application of deprescribing tools; and drivers and barriers to overcome for successful implementation in the healthcare system.

Medicine --- Pharmaceutical industries --- acute kidney injury --- early biomarker --- plasma neutrophil gelatinase-associated lipocalin --- soluble urokinase plasminogen activator receptor --- medication optimization --- older patients --- emergency department --- multimorbidity --- polypharmacy --- potentially inappropriate medication use --- older adults --- prevalence --- determinants --- chronic --- outpatient --- 2019 Beers criteria --- Ethiopia --- pharmacogenomics --- persons with diabetes --- drug–drug interactions --- drug–gene interactions --- cytochrome P450 --- SLCO1B1 --- drug interaction checkers --- adverse drug reactions --- pharmacogenetics --- personalized medicine --- phenprocoumon --- DOACs --- bleeding --- thromboembolism --- HLA --- drug hypersensitivity --- abacavir --- allopurinol --- flucloxacillin --- antiepileptic drugs --- cost-effectiveness --- shared medication record --- medication reconciliation --- drug information service --- hospital pharmacy service --- electronic prescribing --- electronic medical record --- clinical pharmacist --- CYP2D6 --- CYP2D7P --- CYP2D8P --- copy number variation --- CNV --- genotyping --- 5’nuclease assay --- HRM --- high resolution melting --- drug metabolization --- extracellular vesicles --- exosomes --- microvesicles --- pharmacogene expression --- medication review --- deprescriptions --- quality of life --- aged --- aged, 80 and over --- nursing homes --- deprescribing --- medication-based risk score --- health outcomes --- cytochromes --- CYP1A2 --- adverse drug reaction --- antipsychotics --- olanzapine --- clozapine --- loxapine --- children --- youth --- digital decision-support --- health services research --- general practice --- process evaluation --- antidepressants --- utility --- population-based --- appropriateness --- medication adherence --- digital health